ANI Pharmaceuticals, Inc. (ANIP): Price and Financial Metrics


ANI Pharmaceuticals, Inc. (ANIP): $40.66

0.65 (+1.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANIP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ANIP POWR Grades

  • ANIP scores best on the Growth dimension, with a Growth rank ahead of 95.87% of US stocks.
  • The strongest trend for ANIP is in Growth, which has been heading up over the past 179 days.
  • ANIP's current lowest rank is in the Quality metric (where it is better than 5.83% of US stocks).

ANIP Stock Summary

  • With a year-over-year growth in debt of 41.95%, ANI PHARMACEUTICALS INC's debt growth rate surpasses 77.98% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, ANI PHARMACEUTICALS INC is reporting a growth rate of 257.84%; that's higher than 93.43% of US stocks.
  • ANI PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -22.42%, greater than the shareholder yield of only 18.46% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ANI PHARMACEUTICALS INC are TKNO, JMIA, KPLT, MRAI, and CBT.
  • ANIP's SEC filings can be seen here. And to visit ANI PHARMACEUTICALS INC's official web site, go to www.anipharmaceuticals.com.

ANIP Valuation Summary

  • ANIP's EV/EBIT ratio is -15.2; this is 276.74% lower than that of the median Healthcare stock.
  • Over the past 243 months, ANIP's EV/EBIT ratio has gone down 12.4.

Below are key valuation metrics over time for ANIP.

Stock Date P/S P/B P/E EV/EBIT
ANIP 2022-11-25 2.6 2.3 -10.5 -15.2
ANIP 2022-11-23 2.5 2.3 -10.1 -14.8
ANIP 2022-11-22 2.5 2.2 -10.1 -14.8
ANIP 2022-11-21 2.4 2.2 -9.7 -14.3
ANIP 2022-11-18 2.4 2.2 -10.0 -14.6
ANIP 2022-11-17 2.4 2.2 -10.0 -14.6

ANIP Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 222.28%.
  • Its 4 year price growth rate is now at -35.19%.
  • Its 3 year cash and equivalents growth rate is now at 89.43%.
Over the past 70 months, ANIP's revenue has gone up $154,460,000.

The table below shows ANIP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 283.082 -38.988 -69.197
2022-06-30 251.322 -48.013 -64.638
2022-03-31 226.092 -36.288 -63.414
2021-12-31 216.136 3.322 -42.793
2021-09-30 212.459 9.798 -22.102
2021-06-30 213.377 13.586 -17.221

ANIP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANIP has a Quality Grade of D, ranking ahead of 9.89% of graded US stocks.
  • ANIP's asset turnover comes in at 0.453 -- ranking 96th of 682 Pharmaceutical Products stocks.
  • NWBO, CYTR, and NAII are the stocks whose asset turnover ratios are most correlated with ANIP.

The table below shows ANIP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.453 0.570 -0.047
2021-06-30 0.457 0.592 -0.029
2021-03-31 0.460 0.600 -0.018
2020-12-31 0.446 0.582 -0.047
2020-09-30 0.427 0.596 -0.063
2020-06-30 0.425 0.619 -0.054

ANIP Price Target

For more insight on analysts targets of ANIP, see our ANIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.00 Average Broker Recommendation 1.75 (Moderate Buy)

ANIP Stock Price Chart Interactive Chart >

Price chart for ANIP

ANIP Price/Volume Stats

Current price $40.66 52-week high $51.69
Prev. close $40.01 52-week low $22.31
Day low $39.77 Volume 54,300
Day high $41.67 Avg. volume 99,462
50-day MA $35.87 Dividend yield N/A
200-day MA $32.94 Market Cap 710.13M

ANI Pharmaceuticals, Inc. (ANIP) Company Bio


ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company was founded in 2004 and is based in Baudette, Minnesota.


ANIP Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIP Latest Social Stream


Loading social stream, please wait...

View Full ANIP Social Stream

Latest ANIP News From Around the Web

Below are the latest news stories about ANI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ANIP as an investment opportunity.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

BAUDETTE, Minn., November 28, 2022--ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL.

Yahoo | November 28, 2022

This Biopharma 'Fits the Bill' as a Growth Play

With the economy looking like it is heading towards recession in 2023, reliable growth names with reasonable valuations are in short supply in the current market. ANI Pharmaceuticals is a roughly $650 million market cap specialty pharmaceutical company focused on the development and marketing of generic and branded drugs with niche or high barrier to entry characteristics. The Minnesota-based company's product portfolio consists of approximately 85 generic products and 15 branded drugs.

Yahoo | November 27, 2022

ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP

BAUDETTE, Minn., November 16, 2022--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100 mg.

Yahoo | November 16, 2022

ANI Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

ANI Pharmaceuticals ( NASDAQ:ANIP ) Third Quarter 2022 Results Key Financial Results Revenue: US$83.8m (up 61% from 3Q...

Yahoo | November 11, 2022

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Read More 'ANIP' Stories Here

ANIP Price Returns

1-mo 5.36%
3-mo 9.89%
6-mo 39.06%
1-year -1.17%
3-year -34.01%
5-year -42.46%
YTD -11.76%
2021 58.68%
2020 -52.91%
2019 36.98%
2018 -30.15%
2017 6.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8135 seconds.